16th Jun 2014 10:22
LONDON (Alliance News) - Horizon Discovery Group PLC Monday said it has been awarded a GBP360,224 research grant from the UK's Technology Strategy Board, together with life sciences testing firm LGC Ltd to develop standardisation for next-generation cancer diagnostics.
Horizon said it will receive more than half of the funding. The Technology Strategy Board is a UK public body set up by the Department for Business Innovation & Skills to promote science and technology.
The programme will establish methods and cross-platform data sets to standardise existing 'liquid biopsy' genetic diagnostic tests, to determine test sensitivity, and to help drive the development of new more sensitive systems as well as training and proficiency testing schemes for pathology laboratories.
Horizon said it will use its Genesis platform to engineer cell lines carrying cancer genetic markets. These cell lines will be used to generate reference standard material including formalin-fixed paraffin embedded cell blocks and genomic.
LGC will test the reference standard material produced by Horizon. LGC is also developing these methods for accurate and sensitive detection of tumour DNA in the bloodstream.
Horizon shares were quoted down 3.1% at 155.00 pence Monday morning.
By Anthony Tshibangu; [email protected]; @AnthonyAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
HZD.L